CD BioGlyco provides an integrated solution of anti-glycan monoclonal antibody development. Our advanced technology platforms and high-quality services will fully meet your needs. We have confidence to be your essential research assistant in the field of glycobiology.
Carbohydrates are composed of monosaccharide residues linked together by glycosidic bonds with α or β stereochemical properties. There are multiple hydroxyl groups in the monosaccharide structural unit that can serve as attachment sites, and glycosylation can occur at multiple positions at the same time to cause carbohydrate chain branching. Modifications after glycosylation (such as sulfation, phosphorylation and acylation) will further increase its structural diversification, and most glycans are linked to other biological macromolecules to produce glycoconjugates such as glycoproteins and glycolipids. Due to the complex structure of carbohydrates and the lack of genetic coding, many techniques commonly used to identify and monitor proteins are not suitable for carbohydrates.
Although glycans are indispensable in many life activities, the function and mechanism of action of most carbohydrates have not yet been well understood. Currently, monoclonal antibodies have transformed biomedical research and clinical applications. Among them, anti-glycan monoclonal antibodies can be widely used in various applications, such as monitoring/detecting the expression of carbohydrates, regulating biological processes mediated by glycans as agonists/antagonists, purifying glycans/glycoproteins, and discovering carbohydrates related to disease states.
Unfortunately, in terms of quantity and quality, the development of glycan binding monoclonal antibodies lags behind that of anti-protein monoclonal antibodies because of their high structural complexity and the difficulty in determining whether a particular antibody has the appropriate specificity and where to obtain the antibody.
Fig 1. Applications of anti-glycan antibodies in research and clinical therapy (Sterner, E.; et al. 2016)
CD BioGlyco provides more advanced phage display or hybridoma platforms than traditional hybridoma technology. These platforms are almost unrestricted in the production of anti-glycan monoclonal antibodies. In addition to general factors such as suitable host species and isotype, we have also improved methods for evaluating antibody specificity and developed a series of first-class technologies such as ELISA, knockout, knockdown, SPR, glycan microarray and mass spectrometry, and combine them to get the best evaluation scheme. We are also constantly updating and expanding the database, which contains new antibody reagents and the latest information on existing antibodies.
CD BioGlycoes has world-class anti-glycan monoclonal antibody development platforms and antibody specificity evaluation program. Our antibody experts can tailor the optimal solution according to the customer's research project. We can provide you with high-quality and cost-effective services.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.
References:
